More Evidence for Short Term DAPT: Approaching “the Class Effect”

Patients at high risk of bleeding undergoing coronary angioplasty with Orsiro stent can be considered for a short dual antiplatelet scheme. 

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

These data come from the SMART-CHOICE study recently published in JAHA, adding the Orsiro stent to the list of devices supporting 3-month DAPT. 

This study included 2993 patients undergoing coronary angioplasty randomized to 3 moth DAPT followed by P2Y12 inhibitor monotherapy vs 12-month DAPT. 

The original protocol prespecified an analysis of Orsiro patients. In addition, a post hoc analysis compared the Orsiro against the everolimus DES. 

Of the 972 patients receiving the Orsiro, 481 were randomized to a short scheme and 491 to a 12-month DAPT.


Read also: Pleiotropic Effect of Metoprolol: Different From other B-blockers.


After a year, target vessel failure rate (composite of cardiac death, vessel related MI and target vessel revascularization) occurred in 1.7% of patients in the short scheme group vs. 2.9% pf patients in the 12-month group (HR, 0.58; CI 95%, 0.24 to 1.39; p=0.22).

In the general population receiving 3-month DAPT (n=1495) there were no differences in primary end point between patients receiving the Orsiro vs  those receiving the everolimus DES (1.7% versus 1.8%; HR, 0.96; 95% CI, 0.41-2.22; P=0.92).

The Leaders Free study (NEJM 2015) pioneered the efficacy and safety of the polymer-free Biofreedom in a population at high risk of bleeding with a short scheme of just one month DAPT.


Read also: N95 and Surgical Face Mask Sterilization Is Feasible.


Only recently have we found some alternatives to the Biofreedom to treat these patients. It might be just a question of time for us to adopt a short DAPT scheme for all contemporary stents. 

Conclusion

In patients receiving the Orsiro stent, clinical events at one year are similar between patients receiving 3-month DAPT followed by monotherapy with a P2Y12 inhibitor vs 12- month DAPT. In the group with the short scheme, events rate resulted practically identical between the Orsiro and the everolimus DES groups.

JAHA.120.018366frer

Original Title: Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus- Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.

Reference: Kyeong Ho Yun et al. J Am Heart Assoc. 2021;10:e018366. DOI: 10.1161/JAHA.120.018366.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...